Harris & Harris Group, Inc.  

(Public, NASDAQ:TINY)   Watch this stock  
Find more results for Richard Harris
-0.02 (-1.28%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.53 - 1.58
52 week 1.44 - 2.68
Open 1.57
Vol / Avg. 29,390.00/55,168.00
Mkt cap 47.50M
P/E     -
Div/yield     -
EPS -0.72
Shares 30.85M
Beta 1.22
Inst. own 33%
Aug 11, 2016
Q2 2016 Harris and Harris Group Inc Earnings Call - 10:00AM EDT - Add to calendar
Aug 11, 2016
Q2 2016 Harris and Harris Group Inc Earnings Release Add to calendar
Jul 19, 2016
Harris and Harris Group Inc Virtual Roadshow
Jun 7, 2016
Harris and Harris Group Inc Annual Shareholders Meeting
Jun 7, 2016
Harris and Harris Group Inc Analyst Meeting
May 19, 2016
Harris and Harris Group Inc Virtual Roadshow
May 9, 2016
Q1 2016 Harris and Harris Group Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1989.18% -2173.78%
Operating margin -384.69% -781.08%
EBITD margin - -775.84%
Return on average assets -25.91% -19.12%
Return on average equity -28.34% -20.41%
Employees 9 -
CDP Score - -


1450 Broadway Fl 24
NEW YORK, NY 10018-2224
United States - Map
+1-212-5820900 (Phone)
+1-212-5829563 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Harris & Harris Group, Inc. is a non-diversified management investment company operating as a business development company. The Company specializes in making investments in companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences. The Company provides operational and management resources, and financial solutions to such companies. Its investment objective is to achieve long-term capital appreciation by making venture capital investments. It holds interest in various sectors, such as precision health and precision medicine, other BIOLOGY+ and active legacy. Its precision health and precision medicine includes medical technologies, digital technologies, genetic and biochemical technologies, and machine learning technologies. The Company holds interest in over eight portfolio companies that focus on the precision health and precision medicine market.

Officers and directors

Douglas W. Jamison Chairman of the Board, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel B. Wolfe Ph.D. President, Chief Executive Officer, Chief Compliance Officer
Age: 38
Bio & Compensation  - Reuters
Patricia N. Egan CPA Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Mary P. Brady CPA Vice President, Senior Controller
Age: 53
Bio & Compensation  - Reuters
Blake L. Stevens Vice President, Senior Associate
Age: 32
Bio & Compensation  - Reuters
Misti Ushio Ph.D. Chief Strategy Officer , Managing Director
Age: 43
Bio & Compensation  - Reuters
W. Dillaway Dillaway Ayres Jr. Independent Director
Age: 64
Bio & Compensation  - Reuters
Phillip A. Bauman Independent Director
Age: 59
Bio & Compensation  - Reuters
Stacy R Brandom Independent Director
Age: 57
Bio & Compensation  - Reuters
Charles E. Ramsey Independent Director
Age: 72
Bio & Compensation  - Reuters